Agarose-gel electrophoresis for the quality assurance and purity of heparin formulations

The adulteration of raw heparin (Hep) with a synthetic oversulfated chondroitin sulfate (OSCS) not found in nature produced in 2007-2008 a global crisis giving rise to the development of additional, new and specific methods for its quality assurance and purity. In this study, a simple and sensitive agarose-gel electrophoresis method has been developed for the visualization of OSCS in Hep samples along with other natural glycosaminoglycans possibly present as "process-related impurities", in particular dermatan sulfate (DS) and chondroitin sulfate (CS). Agarose-gel electrophoresis under non-conventional conditions is able to separate OSCS from Hep with its two components, the slow-moving and fast-moving species, DS and CS by performing separation for 15 h (overnight) and under high voltage (100 mA, ∼200 V). Densitometric scanning enabled us to calculate a limit of detection of ∼0.5 μg OSCS with a linear behaviour from 0.1 to 5 μg, comparable to CS/DS. Contaminated samples from Hep manufacturers were analyzed and quantitative data were found comparable to previous studies. Due to its capacity to process many samples in a single run and to the equipment commonly available in laboratories, this analytical method would be suitable for the identification and quantification of contamination by other polysaccharides, in particular OSCS and DS, within Hep preparations and formulations.

Abstract aus PubMed (NCBI) für den zitierten Eintrag, in der Originalsprache wiedergegeben. Maßgeblich ist die Fassung der Originalpublikation.

Das Abstract wird nicht übersetzt, damit die eigene Wortwahl der Autoren erhalten bleibt.

The authors developed an agarose-gel electrophoresis method that separates OSCS from heparin alongside natural impurities such as dermatan sulfate and chondroitin sulfate. The 15-hour separation at high voltage gave a detection limit of about 0.5 μg OSCS with linear behavior from 0.1 to 5 μg.

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Weitere begutachtete Studien in der Kategorie „Arzneimittelentwicklung“.

• Hirudotherapie in Medizin und Zahnmedizin — Jha K et al. (2015)
• Blutegeltherapie: eine Geschichte — Hyson J (2005)
• Hirudine der asiatischen medizinischen Blutegelart Hirudinaria manillensis: gleich und doch verschieden — Lukas P et al. (2019)
• Transcriptomic analysis of the salivary gland of medicinal leech Hirudo nipponia — Lu Z et al. (2018)
• Molekulardynamische und pharmakologische Untersuchungen an durch Protein-Engineering erzeugten Hirudin-Varianten von Hirudinaria manillensis und Hirudo medicinalis — Sun Y et al. (2022)
• Zellfreie Synthese der Hirudin-Variante 1 des blutsaugenden Egels Hirudo medicinalis — Wüstenhagen D et al. (2020)
• Produktion von Hirudin-Varianten durch gentechnisch veränderte mikrobielle Zellfabriken — Zhang J, Lan N (2018)
• Hirudin bei heparininduzierter Thrombozytopenie — Lubenow N, Greinacher A (2002)
• Hirudin verbessert die diabetische Nephropathie durch Hemmung der Gsdmd-vermittelten Pyroptose — Han J et al. (2023)
• Hirudin als alternatives Antikoagulans – eine historische Übersicht — Markwardt F (2002)

Alle von der ASH analysierten Studien →